NEOVASCULAR-TARGETING CONTRAST MEDIUM COMPOSITION AND METHOD FOR PREPARING SAME

Abstract

The present invention relates to a neovascular-targeting contrast medium composition and a method for preparing same. The neovascular-targeting contrast medium composition according to the present invention exhibits high binding force to neovascularization-associated α.sub.vβ.sub.3 integrin, excellent tissue permeability and biostability, enables simple measurement in vitro, in vivo, or ex vivo, and thus is effective in the detection of neovascularization and in diagnosing diseases associated therewith, and therefore may be usefully employed in the relevant industries.

Claims

1. A neovascular-targeting contrast medium composition comprising: an α.sub.vβ.sub.3 integrin targeting nanobody encoded by at least one kind of base sequence selected from a group consisting of base sequences represented by SEQ ID NOs: 1 to 10; and a probe labeled with a radioactive isotope.

2. The neovascular-targeting contrast medium composition of claim 1, wherein the base sequence represented by SEQ ID NO: 1 encodes an amino acid sequence of the nanobody represented by SEQ ID NO: 11, a base sequence represented by SEQ ID NO: 2 encodes an amino acid sequence thereof represented by SEQ ID NO: 12, and a base sequence represented by SEQ ID NO: 3 encodes an amino acid sequence thereof represented by SEQ ID NO: 13.

3. The neovascular-targeting contrast medium composition of claim 1, wherein the nanobody includes a variable region of a heavy chain antibody (VHH) derived from Camelidae.

4. The neovascular-targeting contrast medium composition of claim 1, wherein in the probe labeled with the radioactive isotope, the radioactive isotope includes one of C-11, N-13, O-15, F-18, Ru-82, Ga-68, Cu-60, Cu-61, Cu-62, Cu-64, Cu-67, K-38, Rb-82, Sc-44, I-123, I-124, I-125, Zr-89, Y-86, Y-90, Lu-177, In-111 and Tc-99m.

5. The neovascular-targeting contrast medium composition of claim 4, wherein the probe labeled with the radioactive isotope includes a compound represented by a following Chemical Formula 1: ##STR00005## (wherein in the Chemical Formula 1, each of R.sup.1 to R.sup.5 represents hydrogen or halogen, R.sup.6 represents C-11, N-13, O-15, F-18, Ru-82, Ga-68, Cu-60, Cu-61, Cu-62, Cu-64, Cu-67, K-38, Rb-82, Sc-44, I-123, I-124, I-125, Zr-89, Y-86, Y-90, Lu-177, In-111 or Tc-99m).

6. The neovascular-targeting contrast medium composition of claim 5, wherein the radioactive isotope-labeled probe includes a compound represented by a following Chemical Formula 2: ##STR00006##

7. The neovascular-targeting contrast medium composition of claim 1, wherein the contrast medium composition is used for positron emission tomography (PET) imaging, computed tomography (CT) imaging, single-photon emission computed tomography (SPEC) imaging, PET/CT imaging, PET/MRI imaging, or PET/optical imaging, and PET/MR/optical imaging.

8. A method for diagnosing angiogenesis-related diseases, comprising: administering the neovascular-targeting contrast medium composition of claim 1 to a subject: and determining a presence of the angiogenesis-related diseases in the subject based on an image signal.

9. The method claim 8, wherein the angiogenesis-related disease includes at least one kind selected from a group consisting of arteriosclerosis, cancer, diabetic retinopathy, angiogenesis glaucoma, posterior lens fibrosis, proliferative vitreous retinopathy, immature retinopathy, ophthalmic inflammation, corneal ulcer, conical cornea, macular degeneration, Sjogren's syndrome, myopic tumor, corneal graft rejection, abnormal wound union, trachoma, bone disease, rheumatoid arthritis, osteoarthritis, septicemia arthritis, hemangiomas, angiofibroma, psoriasis, pyogenic granuloma, proteinuria, abdominal aortic aneurysm disease, degenerative cartilage loss due to traumatic joint damage, neuro demyelination disease, liver cirrhosis, glomerular disease, immature rupture of the embryonic membrane, inflammatory bowel disease, periodontal ligament disease, restenosis, inflammation of the central nervous system, Alzheimer's disease, skin aging, thyroid hyperplasia, and Grave's disease.

10. A method for diagnosing cancers, comprising: administering the neovascular-targeting contrast medium composition of claim 1 to a subject, and determining a presence of the angiogenesis-related diseases in the subject based on an image signal.

11. The method of claim 10, wherein the cancer includes at least one kind selected from a group consisting of skin cancer, prostate cancer, breast cancer, cervical cancer, colon cancer, lung cancer, gallbladder cancer, pancreatic cancer, gastric cancer, ovarian cancer, malignant melanoma, malignant lymphoma, thyroid cancer, metastatic brain tumor and brain glioma.

12. A method for preparing a neovascular-targeting contrast medium, the method comprising: a step (step 1) of reacting an α.sub.vβ.sub.3 integrin targeting nanobody encoded by at least one kind of base sequence selected from a group consisting of base sequences represented by SEQ ID NOs: 1 to 10 with a probe labeled with a radioactive isotope in a buffer solution at pH 8.0 or higher: ##STR00007## (wherein in the Reaction Formula 1, each of R.sup.1 to R.sup.5 represents hydrogen or halogen, R.sup.6 represents C-11, N-13, O-15, F-18, Ru-82, Ga-68, Cu-60, Cu-61, Cu-62, Cu-64, Cu-67, K-38, Rb-82, Sc-44, I-123, I-124, I-125, Zr-89, Y-86, Y-90, Lu-177, In-111 or Tc-99m).

Description

BRIEF DESCRIPTIONS OF THE DRAWING

[0021] FIG. 1 is the result of identifying a radiochemical yield of the neovascular-targeting contrast medium.

[0022] FIG. 2 is a diagram showing the results of identifying the α.sub.vβ.sub.3 integrin targeting effects of the neovascular-targeting contrast medium according to the present disclosure and of a positive control (.sup.18F-cRGDfk) at the tumor site.

[0023] FIG. 3 is a diagram showing the results of identifying the α.sub.vβ.sub.3 integrin targeting effect of the neovascular-targeting contrast medium according to the present disclosure at the tumor site.

[Modes of the Invention]

[0024] Hereinafter, the present disclosure will be described in detail.

[0025] Neovascular-targeting contrast medium composition

[0026] The present disclosure provides a neovascular-targeting contrast medium composition containing an α.sub.vβ.sub.3 integrin targeting nanobody encoded by at least one kind of base sequence selected from the group consisting of base sequences represented by SEQ ID NOs: 1 to 10; and a probe labeled with a radioactive isotope.

[0027] The term “integrin” in the present disclosure refers to a receptor molecule that exists on the cell surface and acts when cells adhere to extracellular matrix such as fibronectin and collagen. The integrin refers to a transmembrane glycoprotein composed of heterodimers of two subunits, that is, α and β subunits. The existence of 21 types of integrins has been revealed so far. Among them, α.sub.vβ.sub.3 integrin has been reported to play a very important role in maintaining the structure of the cardiovascular system and bone tissue.

[0028] The term “nanobody” in the present disclosure refers to an antibody in which a CDR is a portion of a single domain polypeptide, and includes heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies. In order to distinguish the nanobody from the VH of the 4-chain immunoglobulin, the nanobody is referred to as a variable region of a heavy chain antibody (VHH), a single-domain antibody, or an sdAb.

[0029] The nanobody according to the present disclosure refers to a naturally occurring single domain antibody derived from a heavy chain naturally free of a light chain, and acts as a specific antibody to α.sub.vβ.sub.3 integrin, and has a molecular weight of about 14 KDa to 15 KDa. The nanobody according to the present disclosure is an antibody that is a VHH derived from Camelidae, and may be derived from camels, dromedaries, llama, alpaca and wild llama. To achieve the goal of targeting α.sub.vβ.sub.3 integrin related to angiogenesis, species other than Camelidae may naturally produce the nanobody as heavy chain antibodies without light chains. However, the present disclosure is not limited thereto.

[0030] The nanobody according to the present disclosure is about 10 times smaller than an IgG molecule and is very stable as single polypeptides and are stable under extreme pH and temperature conditions. Further, the nanobody is resistant to the action of proteases, unlike conventional antibodies. When expressed in vitro, mass production of the nanobody may be realized at a high yield.

[0031] The base sequence represented by SEQ ID NO: 1 encodes the amino acid sequence of the nanobody represented by SEQ ID NO: 11. The base sequence represented by SEQ ID NO: 2 encodes the amino acid sequence thereof represented by SEQ ID NO: 12. The base sequence represented by SEQ ID NO: 3 may encode the amino acid sequence thereof represented by SEQ ID NO: 13. Further, the amino acid sequences containing the His6 tag in SEQ ID NOs: 1, 2 or 3 may be represented by amino acids of SEQ ID NOs: 14, 15 and 16, respectively.

[0032] In an embodiment of the present disclosure, in the probe labeled with the radioactive isotope, the radioactive isotope may include one of C-11, N-13, O-15, F-18, Ru-82, Ga-68, Cu-60, Cu-61, Cu-62, Cu-64, Cu-67, K-38, Rb-82, Sc-44, I-123, I-124, I-125, Zr-89, Y-86, Y-90, Lu-177, In-111 and Tc-99m. Preferably, the probe may be a compound represented by a following Chemical Formula 1.

##STR00002##

[0033] (In the Chemical Formula 1,

[0034] each of R.sup.1 to R.sup.5 represents hydrogen or halogen, [0035] R.sup.6 represents C-11, N-13, O-15, F-18, Ru-82, Ga-68, Cu-60, Cu-61, Cu-62, Cu-64, Cu-67, K-38, Rb-82, Sc-44, I-123, I-124, I-125, Zr-89, Y-86, Y-90, Lu-177, In-111 or Tc-99m).

[0036] More preferably, the radioactive isotope-labeled probe may include a compound represented by a following Chemical Formula 2.

##STR00003##

[0037] Contrast Medium Composition for Diagnosing Angiogenesis-Related Disease

[0038] Further, the present disclosure provides a contrast medium composition for diagnosing angiogenesis-related diseases, the composition containing an α.sub.vβ.sub.3 integrin targeting nanobody encoded by at least one kind of base sequence selected from the group consisting of base sequences represented by SEQ ID NOs: 1 to 10; and a probe labeled with a radioactive isotope.

[0039] In one embodiment of the present disclosure, the contrast medium composition may be used for positron emission tomography (PET) imaging, computed tomography (CT) imaging, single-photon emission computed tomography (SPEC) imaging, PET/CT imaging, PET/MRI imaging, or PET/optical imaging, PET/MR/optical imaging.

[0040] In one embodiment of the present disclosure, the angiogenesis-related disease may include at least one kind selected from the group consisting of arteriosclerosis, cancer, diabetic retinopathy, angiogenesis glaucoma, posterior lens fibrosis, proliferative vitreous retinopathy, immature retinopathy, ophthalmic inflammation, corneal ulcer, conical cornea, macular degeneration, Sjogren's syndrome, myopic tumor, corneal graft rejection, abnormal wound union, trachoma, bone disease, rheumatoid arthritis, osteoarthritis, septicemia arthritis, hemangiomas, angiofibroma, psoriasis, pyogenic granuloma, proteinuria, abdominal aortic aneurysm disease, degenerative cartilage loss due to traumatic joint damage, neuro demyelination disease, liver cirrhosis, glomerular disease, immature rupture of the embryonic membrane, inflammatory bowel disease, periodontal ligament disease, restenosis, inflammation of the central nervous system, Alzheimer's disease, skin aging, thyroid hyperplasia, and Grave's disease.

[0041] Contrast Medium Composition for Diagnosing Cancers

[0042] Further, the present disclosure provides a contrast medium composition for diagnosing cancers, the composition containing an α.sub.vβ.sub.3 integrin targeting nanobody encoded by at least one kind of base sequence selected from the group consisting of base sequences represented by SEQ ID NOs: 1 to 10; and a probe labeled with a radioactive isotope.

[0043] In one embodiment of the present disclosure, the cancer may be at least one kind selected from the group consisting of skin cancer, prostate cancer, breast cancer, cervical cancer, colon cancer, lung cancer, gallbladder cancer, pancreatic cancer, gastric cancer, ovarian cancer, malignant melanoma, malignant lymphoma, thyroid cancer, metastatic brain tumor and brain glioma.

[0044] Method for Preparing Neovascular-Targeting Contrast Medium

[0045] Furthermore, the present disclosure provides a method for preparing a neovascular-targeting contrast medium, the method including a step (step 1) of reacting an α.sub.vβ.sub.3 integrin targeting nanobody encoded by at least one kind of base sequence selected from the group consisting of base sequences represented by SEQ ID NOs: 1 to 10, and a probe labeled with a radioactive isotope in a buffer solution at pH 8.0 or higher:

##STR00004##

[0046] In the method for preparing the neovascular-targeting contrast medium acceding to the present disclosure, the step 1 is characterized in that the buffer solution having a pH of 8.0 or higher is an amine-free buffer. Preferably, the buffer solution may include sodium bicarbonate (NaHCO.sub.3) aqueous solution, Tris buffer, and phosphate buffer.

EXAMPLES

[0047] Hereinafter, the present disclosure will be described in more detail based on following Examples. However, the following Examples are only to illustrate the present disclosure, and the content of the present disclosure is not limited to the following 15 Examples.

<Example 1>Preparation of Neovascular-Targeting Contrast Medium

[0048] Synthesis of 2,3,5,6-tetrafluorophenyl-6-[.sup.18F]-fluoronicotinate) was made using a known method.

[0049] 2,3,5,6-tetrafluorophenyl-6-[18F]-fluoronicotinate 86 mCi (millicurie) and 0.5 mg of nanobody reacted with each other in 0.2 ml of 0.1M concentration of sodium bicarbonate (NaHCO.sub.3) aqueous solution at room temperature for 10 minutes. After removing the unreacted material using a size exclusion column (PD-10, GE Healthcare), a final 43 mCi .sup.18F-nanobody was prepared.

[0050] .sup.18F-nanobodeis were prepared using nanobodies containing Lysine and His6 tags in base sequence SEQ ID No: 1, respectively and abbreviated as Nbs-#1 and Nbs-#2, respectively.

[0051] Table 1 shows the results of identifying the radioactivity of aliquots sequentially taken by 300 μL using a PD-10 column.

TABLE-US-00001 TABLE 1 vial Activity (uCi/300 μL) 1 2 2 0 3 55 4 114 5 990 6 4100 7 8400 8 8410 9 4700 10 2900 11 640 12 180

<Experimental Example 1>Identification of Neovascular-Targeting Contrast Medium Labeling Ability

[0052] For the .sup.18F-nanobody prepared in Example 1, a radiochemical yield was identified using Radio-TLC. The results are shown in FIG. 1.

[0053] As shown in FIG. 1, when 2,3,5,6-tetrafluorophenyl-6-[.sup.18F]-fluoronicotinate and the nanobody reacted with each other at room temperature for 10 minutes, the radiochemical yield was greater than or equal to 93%.

<Experimental Example 2>Identification of α.SUB.v.β.SUB.3.Integrin Targeting Effect of .SUP.18.F-Nanobody Targeting Angiogenesis According to the Present Disclosure in Tumor Site

[0054] In order to identify the contrast effect of the contrast medium composition according to the present disclosure as prepared in the Example 1 in the tumor mouse animal model, the following experiment was performed.

[0055] The α.sub.vβ.sub.3 integrin targeting effect was identified using .sup.18F-cRGDfk as a positive control.

[0056] Specifically, an animal model was produced by xenografting (inoculation) U87-MG cells into Athymic nude mice (female, 6-8 weeks old). When the tumor grew to a size of 0.8 cm to 1 cm, the contrast medium was injected into the tail vein (1 mg/kg) to analyze the contrast effect over time. The results are shown in FIG. 2 and FIG. 3.

[0057] As shown in FIG. 2, it was identified that at 1 hour after intravenous injection of .sup.18F-cRGDIk or .sup.18F-nanobody, PET image signals were expressed at the tumor sites of the mice of both groups. It was identified that the tumor site of the mouse injected with .sup.18F-nanobody exhibited a clearer image signal than that of the mouse injected with .sup.18F-cRGDfk.

[0058] As shown in FIG. 3, it was identified that the location of the mouse tumor was accurately indicated for 1 hour, 2 hours and 3 hours after injection of .sup.18F-nanobody.

[0059] The preferred examples of the present disclosure have been described. Those of ordinary skill in the technical field to which the present disclosure belongs will be able to understand that the present disclosure may be implemented in a modified form within a range that does not deviate from the essential characteristics of the present disclosure. Therefore, the disclosed Examples should be considered not in a limiting manner but in an illustrative manner. The scope of the present disclosure is indicated in the claims, not the foregoing description. Any changes within the equivalent scope thereof are included in the present disclosure.